GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.


Renal cell carcinoma (RCC) by Prof. David Pfister, University Hospital of Cologne, Germany

 

After finishing medical school in November 2004 Dr Pfister started his residency in the Department of Urology at the University of Cologne. For his endoscopic training, he switched to the General Hospital in Weiden (Oberpfalz/Bavaria) between August 2006 and March 2007. After returning to Cologne Dr Pfister heightened my oncologic education under Prof. Heidenreich. The oncologic training consisted of two arms: medical and surgical oncology. In 2009 his education was augmented at the University Hospital of Aachen. In 2010 he passed his urologic board exam. Since 2011 Dr Pfister has been working as a staff urologist with main interests in castration-resistant prostate cancer and testicular cancer. In 2011 he passed the Charles Huggins grant, an educational grant at the Center for Prostate Disease Research in Maryland, USA. In 2012 Dr Pfister received an additional qualification in the systemic treatment of solid tumours and since that time he has organised and led the urological clinical trial centre. In 2012 Dr Pfister qualified as a Professor and became an Associate Professor in November 2012 for medical oncologic treatment in urological tumours. At the end of 2015 he became the Commissionary Leader of the Urologic Department of the University of Aachen. Since 2016 Dr Pfister has become the Deputy Director of the Department of Urology, Uro-oncology and Robot-Assisted Surgery, University Hospital of Cologne. Special interest is castration-resistant, radiation-resistant prostate cancer and testicular cancer.

Prof. David Pfister has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Merck, MSD, Janssen and Pfizer. 

Programme summary
Watch the video now
Other episodes of this series
Update from ASCO GU 2018

Update from ASCO GU 2018

Episode 4: Urothelial Carcinoma
Update from ASCO GU 2018

Update from ASCO GU 2018

Episode 5 Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

ipcv Interactive Patient Case Video (IPCV)

Episode

1

of 1

episode
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca 
micro-learning Micro learning - Video, slides and more

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Oct 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

2

of 2

episode
Oncology 
Clinical implementation of testing and PARPis in combination with NHAs

Episode 2: Clinical implementation of testing and PARP inhibitors in combination with NHAs

Experts
Dr Andrew J. Armstrong
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
animated-video Animated Video

Episode

1

of 2

episode
Oncology 
Clinical implementation of testing and PARPi as monotherapy

Episode 1: Clinical implementation of testing and PARPi monotherapy

Experts
Dr Neal Shore
Endorsed by
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Video podcast
Oncology 
Which mCSPC patients benefit from early treatment intensification?

A podcast from GU oncology experts

Experts
Assoc. Prof. Shilpa Gupta, Dr Fabio Schutz
  • download Downloadable
    Resources
  • clock 22 MIN
  • calendar Mar 2023
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer
conference-update Conference update
Oncology 
Highlights from ESMO 2026

Experts join us at ESMO 2026 to share their insights on new data on GI, liver, lung, breast and GU cancers

Experts
Dr Elizabeth Smyth, Dr Yelena Janjigian, Assoc. Prof. Gerald Prager, Prof. Hong Jae Chon, Assoc. Prof. Lorenza Rimassa, Dr Tom Newsom-Davis, Dr Louise Lim, Dr Komal Jhaveri, Dr Roberto Iacovelli
Endorsed by
  • download Downloadable
    Resources
  • clock 9 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education